Huntington National Bank Sells 2,356 Shares of Vertex Pharmaceuticals Incorporated $VRTX

by · The Markets Daily

Huntington National Bank decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 6.6% during the 2nd quarter, HoldingsChannel reports. The fund owned 33,412 shares of the pharmaceutical company’s stock after selling 2,356 shares during the period. Huntington National Bank’s holdings in Vertex Pharmaceuticals were worth $14,875,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at $25,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares in the last quarter. Access Investment Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $27,000. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at $32,000. Finally, American National Bank & Trust boosted its holdings in shares of Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after acquiring an additional 67 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 1.0%

NASDAQ VRTX opened at $421.67 on Wednesday. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The business’s 50-day moving average price is $403.14 and its two-hundred day moving average price is $430.65. The firm has a market capitalization of $108.11 billion, a PE ratio of 30.14 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, beating the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the company earned $4.38 EPS. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on VRTX shares. Leerink Partnrs raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. Scotiabank cut their price objective on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. Royal Bank Of Canada reduced their price target on Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating on the stock in a research report on Tuesday. Barclays upped their price target on Vertex Pharmaceuticals from $408.00 to $414.00 and gave the company an “equal weight” rating in a research report on Tuesday. Finally, HC Wainwright reduced their price target on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $489.45.

View Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

See Also

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).